Ruptured hepatocellular carcinoma following administration of Lenvatinib: An autopsy case

Kumichika Uchida; Toru Aoyama; Yuji Terai; Naomi Yamaguchi; Shingo Kato; Koji Yakabi; Jun Kikuchi; Sachiko Ogasawara; Hirohisa Yano; Sumiko Nagoshi

doi:10.2957/kanzo.63.238

Ruptured hepatocellular carcinoma following administration of Lenvatinib: An autopsy case

Kumichika Uchida, Toru Aoyama, Yuji Terai, Naomi Yamaguchi, Shingo Kato, Koji Yakabi, Jun Kikuchi, Sachiko Ogasawara, Hirohisa Yano, Sumiko Nagoshi

Research output: Contribution to journal › Article › peer-review

Abstract

Lenvatinib was prescribed to a 71-year-old man with hepatocellular carcinoma (210 mm, largest dimension) and portal vein tumor thrombosis. However, this treatment was discontinued 8 days later due to prolongation of prothrombin time and an increase in AST and LDH levels. Rupture of the hepatocellular carcinoma occurred 4 days after discontinuing Lenvatinib and the patient died. Autopsy findings showed a moderately differenti- ated hepatocellular carcinoma with diffuse hemorrhagic necrosis. Immunohistochemistry revealed diffuse FGF 19 protein expression in the nuclei of tumor cells, whereas some of the nuclei and cytoplasm of the hepatocytes in non-tumorous tissue were only slightly stained. The risk of hepatocellular carcinoma rupture should always be considered even after stopping short-term chemotherapy with Lenvatinib.

Original language	English
Pages (from-to)	238-245
Number of pages	8
Journal	Acta Hepatologica Japonica
Volume	63
Issue number	5
DOIs	https://doi.org/10.2957/kanzo.63.238
Publication status	Published - 2022
Externally published	Yes

Keywords

FGF-19
Hepatocellular carcinoma
Lenvatinib
Pathological findings
Rupture

ASJC Scopus subject areas

Hepatology

Access to Document

10.2957/kanzo.63.238

Cite this

@article{c66b7ca8465a44dc8c40543ec1beaf7c,

title = "Ruptured hepatocellular carcinoma following administration of Lenvatinib: An autopsy case",

abstract = "Lenvatinib was prescribed to a 71-year-old man with hepatocellular carcinoma (210 mm, largest dimension) and portal vein tumor thrombosis. However, this treatment was discontinued 8 days later due to prolongation of prothrombin time and an increase in AST and LDH levels. Rupture of the hepatocellular carcinoma occurred 4 days after discontinuing Lenvatinib and the patient died. Autopsy findings showed a moderately differenti- ated hepatocellular carcinoma with diffuse hemorrhagic necrosis. Immunohistochemistry revealed diffuse FGF 19 protein expression in the nuclei of tumor cells, whereas some of the nuclei and cytoplasm of the hepatocytes in non-tumorous tissue were only slightly stained. The risk of hepatocellular carcinoma rupture should always be considered even after stopping short-term chemotherapy with Lenvatinib.",

keywords = "FGF-19, Hepatocellular carcinoma, Lenvatinib, Pathological findings, Rupture",

author = "Kumichika Uchida and Toru Aoyama and Yuji Terai and Naomi Yamaguchi and Shingo Kato and Koji Yakabi and Jun Kikuchi and Sachiko Ogasawara and Hirohisa Yano and Sumiko Nagoshi",

note = "Publisher Copyright: {\textcopyright} 2022 The Japan Society of Hepatology..",

year = "2022",

doi = "10.2957/kanzo.63.238",

language = "English",

volume = "63",

pages = "238--245",

journal = "Acta Hepatologica Japonica",

issn = "0451-4203",

publisher = "Japan Society of Hepatology",

number = "5",

}

TY - JOUR

T1 - Ruptured hepatocellular carcinoma following administration of Lenvatinib

T2 - An autopsy case

AU - Uchida, Kumichika

AU - Aoyama, Toru

AU - Terai, Yuji

AU - Yamaguchi, Naomi

AU - Kato, Shingo

AU - Yakabi, Koji

AU - Kikuchi, Jun

AU - Ogasawara, Sachiko

AU - Yano, Hirohisa

AU - Nagoshi, Sumiko

PY - 2022

Y1 - 2022

N2 - Lenvatinib was prescribed to a 71-year-old man with hepatocellular carcinoma (210 mm, largest dimension) and portal vein tumor thrombosis. However, this treatment was discontinued 8 days later due to prolongation of prothrombin time and an increase in AST and LDH levels. Rupture of the hepatocellular carcinoma occurred 4 days after discontinuing Lenvatinib and the patient died. Autopsy findings showed a moderately differenti- ated hepatocellular carcinoma with diffuse hemorrhagic necrosis. Immunohistochemistry revealed diffuse FGF 19 protein expression in the nuclei of tumor cells, whereas some of the nuclei and cytoplasm of the hepatocytes in non-tumorous tissue were only slightly stained. The risk of hepatocellular carcinoma rupture should always be considered even after stopping short-term chemotherapy with Lenvatinib.

AB - Lenvatinib was prescribed to a 71-year-old man with hepatocellular carcinoma (210 mm, largest dimension) and portal vein tumor thrombosis. However, this treatment was discontinued 8 days later due to prolongation of prothrombin time and an increase in AST and LDH levels. Rupture of the hepatocellular carcinoma occurred 4 days after discontinuing Lenvatinib and the patient died. Autopsy findings showed a moderately differenti- ated hepatocellular carcinoma with diffuse hemorrhagic necrosis. Immunohistochemistry revealed diffuse FGF 19 protein expression in the nuclei of tumor cells, whereas some of the nuclei and cytoplasm of the hepatocytes in non-tumorous tissue were only slightly stained. The risk of hepatocellular carcinoma rupture should always be considered even after stopping short-term chemotherapy with Lenvatinib.

KW - FGF-19

KW - Hepatocellular carcinoma

KW - Lenvatinib

KW - Pathological findings

KW - Rupture

UR - http://www.scopus.com/inward/record.url?scp=85132822546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85132822546&partnerID=8YFLogxK

U2 - 10.2957/kanzo.63.238

DO - 10.2957/kanzo.63.238

M3 - Article

AN - SCOPUS:85132822546

SN - 0451-4203

VL - 63

SP - 238

EP - 245

JO - Acta Hepatologica Japonica

JF - Acta Hepatologica Japonica

IS - 5

ER -

Ruptured hepatocellular carcinoma following administration of Lenvatinib: An autopsy case

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this